Jamal Hammoud, MD
Endocrinology, Diabetes & Metabolism · Flint, MINPI 1639284672
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $314,152 of the $386,377 with a category attached, or 81.3%. Lilly USA, LLC accounts for 60.2% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $109,095 and has fallen 61.8% since, to $41,689 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,755 payments — averaging $220.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$233K
- Boehringer Ingelheim$40K
- AstraZeneca$37K
- Sanofi-aventis U.S. LLC$22K
- Novo Nordisk$19K
- Johnson & Johnson$15K
- plus $21K from 54 others
Across 1,396 payments — averaging $1570.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$595K
- Sanofi US Services Inc.$501K
- Novo Nordisk AS$361K
- AstraZeneca$234K
- AbbVie$231K
- Bayer$105K
- plus $165K from 7 others
What the payments were for
- Consulting fees$10,6853%
- Speaking & faculty fees$314,15281%
- Travel & lodging$35,5449%
- Food & beverage$25,8587%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$386,377 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 886 | $1,309,270 |
| OzempicSemaglutide | 681 | $1,139,864 |
| MounjaroTirzepatide | 490 | $835,218 |
| JardianceEmpagliflozin | 621 | $711,183 |
| KorlymMifepristone | 22 | $678,476 |
| Tresiba Flextouch U-200Insulin Degludec | 140 | $187,155 |
| JanuviaSitagliptin Phosphate | 156 | $175,908 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 723 | $155,322 |
| Humalog Kwikpen U-100Insulin Lispro | 357 | $133,650 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $131,501 |
| FarxigaDapagliflozin Propanediol | 126 | $127,331 |
| ProliaDenosumab | 60 | $102,192 |
| Novolog FlexpenInsulin Aspart | 237 | $83,920 |
| Humulin R U-500Insulin Regular, Human | 33 | $73,502 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 104 | $56,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $232,551 | $2,170,5321,452 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $18,981 | $1,229,838778 claims |
| Boehringer IngelheimJardiance, Tradjenta | $40,022 | $757,700658 claims |
| Corcept TherapeuticsKorlym | $1,688 | $678,47622 claims |
| MerckJanuvia, Janumet Xr, Janumet | $5,149 | $246,457208 claims |
| AstraZenecaFarxiga | $36,696 | $127,331126 claims |
| AmgenProlia | $1,515 | $102,19260 claims |
| Johnson & JohnsonInvokana | $15,158 | $42,36629 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $321 | $15,5051,234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Flint
- Muhammad BaklehFlint$18K
- Saira SundusFlint$10K
- Abdallah DlewatiFlint$9K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.